CD8A and neoplasm: A recent study demonstrated that low-dose apatinib combined with anti-pd-1 inhibitors optimizes the tumor microenvironment by alleviating hypoxia and promoting CD8 (+) T-cell infiltration37, which was reinforced in our study by the combined application of CPT.